U.S. Markets open in 9 hrs 25 mins
  • S&P Futures

    3,790.25
    -26.50 (-0.69%)
     
  • Dow Futures

    31,084.00
    -152.00 (-0.49%)
     
  • Nasdaq Futures

    12,553.75
    -128.00 (-1.01%)
     
  • Russell 2000 Futures

    2,184.30
    -21.50 (-0.97%)
     
  • Crude Oil

    61.75
    +0.47 (+0.77%)
     
  • Gold

    1,712.50
    -3.30 (-0.19%)
     
  • Silver

    26.22
    -0.17 (-0.63%)
     
  • EUR/USD

    1.2058
    -0.0009 (-0.0723%)
     
  • 10-Yr Bond

    1.4700
    +0.0550 (+3.89%)
     
  • Vix

    26.67
    +2.57 (+10.66%)
     
  • GBP/USD

    1.3954
    +0.0001 (+0.0070%)
     
  • USD/JPY

    107.0100
    +0.0080 (+0.0075%)
     
  • BTC-USD

    49,747.37
    +931.98 (+1.91%)
     
  • CMC Crypto 200

    983.87
    -4.23 (-0.43%)
     
  • FTSE 100

    6,675.47
    +61.72 (+0.93%)
     
  • Nikkei 225

    28,842.96
    -716.14 (-2.42%)
     

Lumos Pharma to Participate in the H.C. Wainwright BioConnect 2021 Conference

  • Oops!
    Something went wrong.
    Please try again later.
Lumos Pharma, Inc.
·2 min read
  • Oops!
    Something went wrong.
    Please try again later.

AUSTIN, Texas, Dec. 18, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the company will participate in the virtual H.C. Wainwright BioConnect 2021 Conference to be held January 11-14, 2021.

H.C. Wainwright BioConnect 2021 Conference

Date:

January 11, 2021

What:

Lumos Pharma Presentation

A webcast of Lumos Pharma’s presentation will be available on-demand as of 6:00AM ET, Monday, January 11, 2021, through the H.C. Wainwright conference portal and on Lumos Pharma’s website under “Events & Presentations” in the Investors & Media section. The webcast will be available on Lumos Pharma’s website for 30 days.

No one-on-one meetings will be held at the presentation - only H.C. Wainwright BioConnect 2021 Conference. Investors are invited to contact Lumos Pharma Investor Relations directly to schedule one-on-one meetings with management.

About Lumos Pharma

Lumos Pharma, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare diseases. Lumos Pharma was founded and is led by a management team with longstanding experience in rare disease drug development and received early funding by leading healthcare investors, including Deerfield Management, a fund managed by Blackstone Life Sciences, Roche Venture Fund, New Enterprise Associates (NEA), Santé Ventures, and UCB. Lumos Pharma’s lead therapeutic candidate is LUM-201, an oral growth hormone stimulating small molecule for the treatment of Pediatric Growth Hormone Deficiency (PGHD). If approved by the FDA, LUM-201 would provide an orally administered alternative to daily injections that current PGHD patients endure for many years of treatment. LUM-201 has received Orphan Drug Designation in both the US and EU. For more information, please visit www.lumos-pharma.com.

Investor & Media Contact:

Lisa Miller
Lumos Pharma Investor Relations
512-792-5454
ir@lumos-pharma.com

Source: Lumos Pharma, Inc.